Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-term risk of colorectal cancer after screen-detected adenoma : Experiences from a Danish gFOBT-positive screening cohort. / Bjerrum, Andreas; Lindebjerg, Jan; Andersen, Ole; Fischer, Anders; Lynge, Elsebeth.

In: International Journal of Cancer, Vol. 147, No. 4, 2020, p. 940-947.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bjerrum, A, Lindebjerg, J, Andersen, O, Fischer, A & Lynge, E 2020, 'Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort', International Journal of Cancer, vol. 147, no. 4, pp. 940-947. https://doi.org/10.1002/ijc.32850

APA

Bjerrum, A., Lindebjerg, J., Andersen, O., Fischer, A., & Lynge, E. (2020). Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort. International Journal of Cancer, 147(4), 940-947. https://doi.org/10.1002/ijc.32850

Vancouver

Bjerrum A, Lindebjerg J, Andersen O, Fischer A, Lynge E. Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort. International Journal of Cancer. 2020;147(4):940-947. https://doi.org/10.1002/ijc.32850

Author

Bjerrum, Andreas ; Lindebjerg, Jan ; Andersen, Ole ; Fischer, Anders ; Lynge, Elsebeth. / Long-term risk of colorectal cancer after screen-detected adenoma : Experiences from a Danish gFOBT-positive screening cohort. In: International Journal of Cancer. 2020 ; Vol. 147, No. 4. pp. 940-947.

Bibtex

@article{004dc9d2273d44418f13baf7c7ca4669,
title = "Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort",
abstract = "Fecal occult blood test (FOBT) screening for colorectal cancer (CRC) is implemented in several countries. Approximately half of all FOBT-positive persons have screen-detected adenomas. Despite removal of these, patients with large/multiple adenomas have increased risk of later developing new advanced adenomas and CRC. International guidelines exist for colonoscopic surveillance following adenoma removal. These divide patients into low-, intermediate- and high-risk groups. We followed 711 FOBT-positive patients with screening adenoma identified during population-based CRC screening in two Danish counties in 2005-2006. As reference population, we included 1,240,348 persons in the same age group from the rest of Denmark not included in the screening. We estimated the long-term CRC risk stratified by adenoma findings during screening and compared to the reference group. After 12 years follow-up, the CRC incidence among all adenoma patients was 322 cases per 100,000 person-years (95{\%} confidence interval [CI]: 212-489) ranging from 251 (95{\%} CI: 94-671) to 542 (95{\%} CI: 300-978) cases per 100,000 person-years in the low- and high-risk groups, respectively. In the reference population, the CRC incidence was 244 (95{\%} CI: 242-247) per 100,000. Patients with screen-detected high-risk adenomas after a positive FOBT had an almost doubled risk of CRC compared to the reference population (adjusted hazard ratio [aHR] 1.95, 95{\%} CI: 1.08-3.51), and the incidence in those with no follow-up visits was over 3.6 (aHR 3.64, 95{\%} CI: 1.82-7.29) times the incidence in the reference population. The increased CRC risk could be controlled if high-risk patients underwent follow-up colonoscopy (aHR 0.87, 95{\%} CI: 0.28-2.69).",
keywords = "colorectal cancer, screening, adenoma, FOBT, OCCULT BLOOD-TESTS, COLONOSCOPY SURVEILLANCE, POLYPECTOMY, QUALITY, INDICATORS, PREVENTION, MORTALITY, SOCIETY, TRIAL, COLON",
author = "Andreas Bjerrum and Jan Lindebjerg and Ole Andersen and Anders Fischer and Elsebeth Lynge",
year = "2020",
doi = "10.1002/ijc.32850",
language = "English",
volume = "147",
pages = "940--947",
journal = "International Journal of Cancer. Supplement",
issn = "0898-6924",
publisher = "JohnWiley & Sons, Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Long-term risk of colorectal cancer after screen-detected adenoma

T2 - Experiences from a Danish gFOBT-positive screening cohort

AU - Bjerrum, Andreas

AU - Lindebjerg, Jan

AU - Andersen, Ole

AU - Fischer, Anders

AU - Lynge, Elsebeth

PY - 2020

Y1 - 2020

N2 - Fecal occult blood test (FOBT) screening for colorectal cancer (CRC) is implemented in several countries. Approximately half of all FOBT-positive persons have screen-detected adenomas. Despite removal of these, patients with large/multiple adenomas have increased risk of later developing new advanced adenomas and CRC. International guidelines exist for colonoscopic surveillance following adenoma removal. These divide patients into low-, intermediate- and high-risk groups. We followed 711 FOBT-positive patients with screening adenoma identified during population-based CRC screening in two Danish counties in 2005-2006. As reference population, we included 1,240,348 persons in the same age group from the rest of Denmark not included in the screening. We estimated the long-term CRC risk stratified by adenoma findings during screening and compared to the reference group. After 12 years follow-up, the CRC incidence among all adenoma patients was 322 cases per 100,000 person-years (95% confidence interval [CI]: 212-489) ranging from 251 (95% CI: 94-671) to 542 (95% CI: 300-978) cases per 100,000 person-years in the low- and high-risk groups, respectively. In the reference population, the CRC incidence was 244 (95% CI: 242-247) per 100,000. Patients with screen-detected high-risk adenomas after a positive FOBT had an almost doubled risk of CRC compared to the reference population (adjusted hazard ratio [aHR] 1.95, 95% CI: 1.08-3.51), and the incidence in those with no follow-up visits was over 3.6 (aHR 3.64, 95% CI: 1.82-7.29) times the incidence in the reference population. The increased CRC risk could be controlled if high-risk patients underwent follow-up colonoscopy (aHR 0.87, 95% CI: 0.28-2.69).

AB - Fecal occult blood test (FOBT) screening for colorectal cancer (CRC) is implemented in several countries. Approximately half of all FOBT-positive persons have screen-detected adenomas. Despite removal of these, patients with large/multiple adenomas have increased risk of later developing new advanced adenomas and CRC. International guidelines exist for colonoscopic surveillance following adenoma removal. These divide patients into low-, intermediate- and high-risk groups. We followed 711 FOBT-positive patients with screening adenoma identified during population-based CRC screening in two Danish counties in 2005-2006. As reference population, we included 1,240,348 persons in the same age group from the rest of Denmark not included in the screening. We estimated the long-term CRC risk stratified by adenoma findings during screening and compared to the reference group. After 12 years follow-up, the CRC incidence among all adenoma patients was 322 cases per 100,000 person-years (95% confidence interval [CI]: 212-489) ranging from 251 (95% CI: 94-671) to 542 (95% CI: 300-978) cases per 100,000 person-years in the low- and high-risk groups, respectively. In the reference population, the CRC incidence was 244 (95% CI: 242-247) per 100,000. Patients with screen-detected high-risk adenomas after a positive FOBT had an almost doubled risk of CRC compared to the reference population (adjusted hazard ratio [aHR] 1.95, 95% CI: 1.08-3.51), and the incidence in those with no follow-up visits was over 3.6 (aHR 3.64, 95% CI: 1.82-7.29) times the incidence in the reference population. The increased CRC risk could be controlled if high-risk patients underwent follow-up colonoscopy (aHR 0.87, 95% CI: 0.28-2.69).

KW - colorectal cancer

KW - screening

KW - adenoma

KW - FOBT

KW - OCCULT BLOOD-TESTS

KW - COLONOSCOPY SURVEILLANCE

KW - POLYPECTOMY

KW - QUALITY

KW - INDICATORS

KW - PREVENTION

KW - MORTALITY

KW - SOCIETY

KW - TRIAL

KW - COLON

U2 - 10.1002/ijc.32850

DO - 10.1002/ijc.32850

M3 - Journal article

C2 - 31894860

VL - 147

SP - 940

EP - 947

JO - International Journal of Cancer. Supplement

JF - International Journal of Cancer. Supplement

SN - 0898-6924

IS - 4

ER -

ID: 244648563